This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
RCTs were included. The inclusion criteria were as follows: randomised, double-blind trial with a placebo-controlled arm; single-dose triptan treatment, with no rescue medications or repeat doses of triptan allowed for 2 hours after the initial dosing;
data from a standard 4-point assessment scale were available for baseline and post-treatment headache severity analysis; and definitive data were available for determining the percentage of patients (in both the treatment and control arms) who were pain free at 2 hours post dose.
Studies were excluded from the meta-analysis on the grounds of lack of relevance. More specifically, not randomised, open label, end points solely pharmacological, use of end points other than pain free, and pain relief used. Studies were also excluded if they used a drug, dose or formulation not approved in the USA.
Data from 8 additional treatment arms from included studies were not incorporated in the meta-analysis because they related to doses below that recommended for most patients (sumatriptan 25 mg, naratriptan 1 mg, rizatriptan 5 mg, and almotriptan 6.25 mg). No data for naratriptan 1 mg were included because this is only indicated in a prophylactic role.
Sources searched to identify primary studies
MEDLINE and EMBASE were searched electronically. The reference lists from primary or benchmark papers and review articles were searched manually.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
The methods used to judge relevance, validity or extracting data were not reported. However, the authors stated that, although direct comparative trials are the ideal means of comparing treatments, only a few studies that involved direct, head-to-head comparisons of triptans were found. Nonetheless, nearly all triptan trials used comparable protocols. For the sake of analysis, it was therefore assumed that all placebo-controlled studies not involving direct comparison of triptans were fundamentally comparable.
Number of primary studies included
Forty-five RCTs were identified in the primary search. An additional 4 studies were identified in the frovatriptan data summary. Twenty-seven of these studies, incorporating 36 active treatment arms, qualified for inclusion in the metaanalysis.
Methods of combining primary studies
The primary studies were combined using a meta-analysis. Combined data for the number-needed-to-treat (NNT) were derived using the random-effects model of DerSimonian and Laird.
Results of the review
The percentage of patients who were pain free within 2 hours after drug administration ranged from 11.6% for frovatriptan 2.5 mg to 40.8% for rizatriptan 10 mg.
The placebo response rates ranged from 2.6% in frovatriptan 2.5 mg studies to 14.4% in almotriptan 12.5 mg studies.
The absolute percentage of patients who were pain free at 2 hours was significantly higher for all triptan doses than for placebo, (p<0.0001).
The NNT values ranged from 3.2 for rizatriptan 10 mg to 11.3 for frovatriptan 2.5 mg.
For sumatriptan 50 mg, the percentage of pain-free patients was 24.6% for the active arm and 5.8% for the placebo arm. The NNT was 5.4 (95% confidence interval, CI: 4.3 -9.4; p<0.01).
For sumatriptan 100 mg, the percentage of pain-free patients was 30.4% for the active arm and 7.8% for the placebo arm. The NNT was 4.7 (95% CI: 4.0 -5.9; p<0.05).
For rizatriptan 10 mg, the percentage of pain-free patients was 40.8% for the active arm and 7.8% for the placebo arm. The NNT was 3.2 (95% CI: 2.9 -3.5; p<0.001).
For zolmitriptan 2.5 mg, the percentage of pain-free patients was 29.2% for the active arm and 8.6% for the placebo arm. The NNT was 5.1 (95% CI: 3.7 -8.2; p<0.05).
For zolmitriptan 5 mg, the percentage of pain-free patients was 31.7% for the active arm and 6.0% for the placebo arm. The NNT was 4.2 (95% CI: 2.9 -7.5; p<0.05).
For naratriptan 2.5 mg, the percentage of pain-free patients was 20.7% for the active arm and 8.4% for the placebo arm. The NNT was 8.2 (95% CI: 5.0 -21.4; p<0.001).
For almotriptan 12.5 mg, the percentage of pain-free patients was 36.0% for the active arm and 14.4% for the placebo arm. The NNT was 4.7 (95% CI: 3.5 -7.0; p<0.01).
For frovatriptan 2.5 mg, the percentage of pain-free patients was 11.6% for the active arm and 2.6% for the placebo arm. The NNT was 11.3 (95% CI: 9.3 -14.3; p<0.0001).
Rizatriptan 10 mg was significantly more effective than all the other triptans except zolmitriptan 5 mg. Although the hierarchy of clinical effectiveness of the triptans was maintained, broader overlaps in the CIs were obtained with the NNT calculation.
Measure of benefits used in the economic analysis
The measure of benefit used for the synthesis with the costs was the number of patients with freedom of pain within 2 hours of the initial dosing. However, the NNT was calculated as the reciprocal of the measure of benefit and was multiplied by the costs in the cost-effectiveness analysis. The NNT was derived from the results of the review.
Direct costs
The only direct cost included was that of prescription drugs. The costs were not discounted as the time horizon was only 2 hours. The only costs considered were those for a single triptan dose since the measure of benefit was defined as freedom of pain within 2 hours. Other quantities and costs (e.g. physician visits and rescue medication) were not analysed. Dosage prices were taken from a retail website. These were lower than those at community pharmacies but were higher than the discounted prices, before member co-payment, available to many managed care organisations. The price year was 2002.
